A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations

Analytical Biochemistry

Volumn 373, Issue 1, 2008, Pages 1-8

  Mao, Shi Shan ^a   DiMuzio, Jillian ^a   McHale, Carolyn ^a   Burlein, Christine ^a   Olsen, David ^a   Carroll, Steven S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Elastase; Hepatitis C; Inhibition; NS3; Protease; Time resolved fluorescence

Indexed keywords

ENERGY TRANSFER; ENZYME ACTIVITY; FLUORESCENCE QUENCHING; FORSTER RESONANCE ENERGY TRANSFER; VIRUSES;

ELASTASE; ENZYME CONCENTRATIONS; FLUORESCENCE ENERGY TRANSFER; HEPATITIS C; NONSTRUCTURAL PROTEINS; NS3 PROTEASE INHIBITORS; PROTEASE; TIME-RESOLVED FLUORESCENCE;

ENZYME INHIBITION;

CILUPREVIR; EUROPIUM; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PROTEINASE; PROTEINASE INHIBITOR; TELAPREVIR;

ARTICLE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME SUBSTRATE; FLUORESCENCE ANALYSIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEPATITIS C VIRUS; NONHUMAN; PRIORITY JOURNAL;

HEPATITIS C VIRUS;

EID: 37049003303     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2007.10.041     Document Type: Article

References (38)

1. Houghton M., Weiner A., Han J., Kou G., and Choo Q.-L. Molecular biology of the hepatitis C virus: implication for diagnosis, development and control of viral disease. Hepatology 14 (1991) 381-399
2. Choo Q.-L., Richman K.H., Han J.H., Berger K., Lee C., Dong C., Gallegos C., Cott D., Medina-Selby A., Barr P.J., Weiner A.J., Bradley D.W., Kuo G., and Houghton M. Genetic organization and diversity of the hepatitis C virus. Proc. Natl. Acad. Sci. USA 88 (1991) 2451-2455
3. Tan S.L., Pause A., Shi Y., and Sonenberg N. Hepatitis C therapeutics: current status and emerging straregies. Nat. Rev. Drug Discov. 1 (2002) 867-881
4. Shepard G.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5 (2005) 558-567
5. De Francesco R., and Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 436 (2005) 953-960
6. Grakoui A., McCourt D.W., Wychowski C., Feinstein S.M., and Rice C.M. Characterization of the hepatitis C virus-encoded serine proteinase: determination of the proteinase-dependent polyprotein cleavage sites. J. Virol. 67 (1993) 2832-2843
7. Hijikata M., Kato N., Ootsuyama Y., Nakagawa M., and Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vivo processing analysis. Proc. Natl. Acad. Proc. USA 88 (1991) 5547-5551
8. Tomei L., Failla C., De Francesco R., and La Monica N. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67 (1993) 4017-4026
9. Lin C., Pragai B.M., Grakoui A., Xu J., and Rice C.M. Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics. J. Virol. 68 (1994) 8147-8157
10. Failla C., Tomei L., and De Francesco R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 68 (1994) 3753-3760
11. Failla C., Tomei L., and De Francesco R. An amino-terminal domain of the hepatitis C NS3 protease is essential for interaction with NS4A. J. Virol. 69 (1995) 1769-1777
12. Lin C., Thomson J.A., and Rice C.M. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J. Virol. 69 (1995) 4373-4380
13. Gale M., and Foy E.M. Evasion of intracellular host defense by hepatitis C virus. Nature 436 (2005) 939-945
14. Goudreau N., and Llinas-Brunet M. The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin. Invest. Drugs 14 (2005) 1129-1144
15. Lamarre D., Anderson P.C., Balley M., Beaulleu P., Bolger G., Bonneau P., Bos M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A., Goudreau N., Kawal S.H., Kukolj G., Lagace L., LaPlante S.R., Narjes H., Poupart M., Rancourt J., Sentjens R.E., St George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.L., and Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426 (2003) 186-314
16. Thomson J.A., and Perni R.B. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Curr. Opin. Drug Disc. Dev. 9 (2006) 606-617
17. Selvin P.R. Fluorescence resonance energy transfer. Methods Enzymol. 246 (1995) 301-335
18. Kakiuchi N., Nishikawa S., Hattori M., and Shimotohno K. A high throughput assay of the hepatitis C virus nonstructural protein s serine protease. J. Virol. Methods 80 (1999) 77-84
19. Spernadio D., Gangloff A.R., Litvak J., Goldsmith R., Hataye J.M., Wang V.R., Shelton E.J., Elrod K., Janc J.W., Clark J.J., Tice K., Weinheimer S., Yeung K., Meanwell N.A., Hernandez D., Staab A.J., Venanles B.L., and Spencer J.R. Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease. Bioorg. Med. Chem. Lett. 12 (2002) 3129-3133
20. Priestley E.S., De Lucca I., Ghavimi B., Erickson-Viitanen S., and Decicco C.P. P1 phenyl peptide boronic acid inhibitors of HCV NS3 protease. Bioorg. Med. Chem. Lett. 12 (2002) 3199-3202
21. Attwood M.R., Bennett J.M., Cambell A.D., Canning G.G.M., Carr M.G., Conway E., Dunsdon R.M., Greening J.R., Jones P.S., Kay P.B., Handa B.K., Hurst D.N., Jennings N.S., Jordan S., Keech E., O'Brien M.A., Overton H.A., King-Underwood J., Raynham T.M., Stenson K.P., Wilkinson C.S., Wilkinson T.C.I., and Wilson F.X. The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A protease. Antiviral Chem. Chemother. 10 (1999) 259-273
22. Pope A.J., Haupts U.M., and Moore K.J. Homogeneous fluorescence readouts from miniaturized high-throughput screening: theory and practice. DDT 4 (1999) 350-362
23. Porcari V., Magnoni L., Terstappen G., and Fecke W. A continuous time-resolved fluorescence assay for identification of BACE1 inhibitors. Assay Drug Dev. Technol. 3 (2005) 287-297
24. Bianchi E., Steinkuhler C., Taliani M., Urbani A., de Francesco R., and Pessi A. Synthetic depsipeptide substrates for the assay of human hepatitis C virus protease. Anal. Biochem. 237 (1996) 39-244
25. Taliani M., Bianchi E., Narjes F., Fossateki M., Urbani A., Steinkuhler C., De Franscesco R., and Pessi A. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrate. Anal. Biochem. 240 (1996) 60-67
26. Gallinari P., Paolini C., Brennan D., Nardi C., Steinkuhler C., and De Francesco R. Modulation of hepatitis C virus NS3 protease and helicase activity through the interaction with NS4A. Biochemistry 38 (1999) 5620-5632
27. Gallinari P., Brennan D., Nardi C., Brunetti M., Tomei L., Steinkuhler C., and De Francesco R. Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus. J. Virol. 72 (1998) 6758-6769
28. Poster presentation at the Digestive Disease Week, May 2006. http://www.arraybiopharma.com/_documents/Publication/PubAttachment192.pdf.
29. Lu L., Pilot-Matias T.J., Stewart K.D., Randolph J.T., Pithawalla R., He W., Huang P.P., Klein L.L., Mo H., and Molls A. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 48 (2004) 2260-2266
30. Lin C., Lin K., Luong Y.-P., Rao B.G., Wei Y.-Y., Brennan D.L., Fulghum J.R., Hsiao H.M., Ma S., Maxwell J.P., Cottrel K.M., Perni R.B., Gates C.A., and Kwong A.D. In vitro resistance studies of hepatitis C virus serine protease inhibitor, VX-950 and BILN-2061. J. Biol. Chem. 279 (2004) 17508-17514
31. Thibeault D., Bousquet C., Gingras R., Lagace L., Maurice R., White P.W., and Lamarre D. Sensitivity of NS3 serine protease from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN-2061. J. Virol. 78 (2004) 7352-7359
32. Llinas-Brunet M., Bailey M.D., Bolger G., Brochu C., Faucher A., Ferland J.M., Garneau M., Ghiro E., Gorys V., Grand-Maitre C., Halmos T., Lapeyre-Paquette N., Liard F., Poirier M., Rheaume M., Tsantrizos Y.S., and Lamarre D. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN-2061. J. Med. Chem. 47 (2004) 1605-1608
33. Ingellinelli P., Altamura S., Bianchi E., Taliani M., Ingenito R., Cortese R., De Francesco R., Steinkuhler C., and Pessi A. Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 37 (1998) 8906-8914
34. Morrison J.F., and Stone S.R. Approach to the study and analysis of the inhibition of enzymes by slow- and tight-binding inhibitors. Comments Mol. Cell. Biophys. 2 (1985) 347-368
35. Steinkuhler C., Biasiol G., Brunetti M., Urbani A., Koch U., Cortese R., Pessi A., and De Francesco R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 37 (1998) 8899-8905
36. Reiser M., Hinrich H., Benhamou Y., Reesink H.W., Wedemeyer H., Avendano C., Riba N., Young C.L., Nehmiz G., and Steinmann G.G. Antiviral efficacy of NS3 protease inhibitor BILN -2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 41 (2005) 832-835
37. Lai M.-T., Di cera E., and Shafer J.A. Kinetic pathway for the slow to fast transition of thrombin. J. Biol. Chem. 48 (1997) 30275-30282
38. Di Cera E., Dang Q.D., and Ayala Y.M. Molecular mechanisms of thrombin function. Cell. Mol. Life Sci. 53 (1997) 701-730